How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

135 results for

Gliptin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients Gliptins and cardiometabolic risk. (PubMed)

Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients Gliptins and cardiometabolic risk. Increased hepatic fat and cardiac fat are common in patients with type 2 diabetes mellitus (T2DM) and are associated with a greater risk of liver fibrosis and cardiovascular (CV) events. Sex-specific differences of dipeptidyl peptidase-four (DPP-4) inhibitor effects on hepatic (HCL) and myocardial fat content (MYCL) have not yet been evaluated.Forty-one T2DM patients (20 male, 21 (...) female) received a gliptin add-on therapy if HbA1c goals were not reached under metformin monotherapy. They underwent cardiac and liver magnetic resonance tomography and spectroscopy before and 6 months after therapy initiation. Plasma samples were analysed for the growth differentiation factor 15 (GDF-15), a novel marker for cardiovascular risk.Thirty-eight patients on gliptin therapy completed the study. We observed a positive correlation between MYCL and HCL before therapy (R = 0·41, P = 0·05

2017 European journal of clinical investigation

3. Diabetes: too many severe adverse effects with gliptins

Diabetes: too many severe adverse effects with gliptins Prescrire IN ENGLISH - Spotlight ''Diabetes: too many severe adverse effects with gliptins'', 1 May 2014 {1} {1} {1} | | > > > Diabetes: too many severe adverse effects with gliptins Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Diabetes: too many severe adverse effects with gliptins (...) Gliptins have no proven efficacy in preventing diabetes complications and can cause severe, even fatal, adverse effects, including pancreatic and skin disorders. It is better to avoid these drugs. Gliptins are commercialised as a diabetes treatment. They have no proven efficacy in preventing diabetes complications and expose patients to a range of sometimes severe adverse effects. The findings of a French pharmacovigilance study confirm the severe adverse effects of gliptins, including pancreatic

2014 Prescrire

4. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid. (PubMed)

Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid. Dipeptidyl peptidase-4 inhibitors (DPP-4i or gliptins) increase the risk of developing bullous pemphigoid (BP). To clarify, whether gliptin-associated BP has special features, we analyzed the clinical, histopathological and immunological features of 27 BP patients, 10 of which previously used gliptin medication. Compared to those who had not previously received gliptins, subjects who (...) had, showed lower BP180-NC16A ELISA (enzyme-linked immunosorbent assay) values, fewer neurological co-morbidities and shorter time to remission, but differences were not statistically significant. The HLA-DQB1*03:01 allele was more commonly present among the BP patients than the control population, but was not more common in those with gliptin history. To determine the effect of gliptins on the expression of the DPP-4/CD-26 protein we performed immunohistochemistry, which showed that the skin

Full Text available with Trip Pro

2019 Acta Dermato-Venereologica

5. Gliptin-Associated Bullous Pemphigoid: A Valuable Model of the Mechanism of Breakdown of Immune Tolerance against BP180. (PubMed)

Gliptin-Associated Bullous Pemphigoid: A Valuable Model of the Mechanism of Breakdown of Immune Tolerance against BP180. The study by Plaquevent et al. strongly supports the recent discovery that the use of gliptins is a risk factor for bullous pemphigoid (BP). However, regarding the phenotype of gliptin-associated BP and the necessity of gliptin withdrawal, clinical data remain scarce. We predict that future studies of gliptin-associated BP will offer valuable information concerning

Full Text available with Trip Pro

2019 Journal of Investigative Dermatology

6. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients (PubMed)

Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients Mucous membrane pemphigoids (MMPs) and bullous pemphigoid (BP) are autoimmune bullous diseases that share physiopathological features: both can result from autoantibodies directed against BP180 or BP230 antigens. An association has been reported between BP and intake of gliptins, which are dipeptidyl peptidase-IV inhibitors used to treat type 2 diabetes mellitus. Clinical and immunological differences have (...) been reported between gliptin-induced BPs and classical BPs: mucosal involvement, non-inflammatory lesions, and target BP180 epitopes other than the NC16A domain. Those findings accorded gliptins extrinsic accountability in triggering MMP onset. Therefore, we examined gliptin intrinsic accountability in a cohort of 313 MMP patients. To do so, we (1) identified MMP patients with gliptin-treated (challenge) diabetes; (2) selected those whose interval between starting gliptin and MMP onset

Full Text available with Trip Pro

2018 Frontiers in immunology

7. A missense variant in GLP1R gene is associated with the glycemic response to treatment with gliptins. (PubMed)

A missense variant in GLP1R gene is associated with the glycemic response to treatment with gliptins. Gliptins act by increasing endogenous incretin levels. Glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic peptide receptor (GIPR) are their indirect drug targets. Variants of GLP1R and GIPR have previously been associated with the incretin effect. The aim of the present pilot study was to examine associations of the GLP1R and GIPR gene variants with the glycaemic (...) response to gliptins. A total of 140 consecutive patients with type 2 diabetes were followed-up 6 months after initiation of gliptin treatment. GLP1R rs6923761 (Gly168Ser) and GIPR rs10423928 genotyping was performed using real-time PCR, with subsequent high-resolution melting analysis. The main study outcome was reduction in glycated haemoglobin (HbA1c) after treatment. GLP1R Gly168Ser variant was significantly associated with reduction in HbA1c in an additive model (β = -0.33, p = 0.011). The mean

2016 obesity & metabolism

8. A Systematic Review and Network Meta-Analysis Assessing the Effectiveness and Tolerability of Gliptins and Sulfonylureas as Monotherapy in Patients with Type 2 Diabetes Mellitus If Metformin is not Considered Appropriate. (PubMed)

A Systematic Review and Network Meta-Analysis Assessing the Effectiveness and Tolerability of Gliptins and Sulfonylureas as Monotherapy in Patients with Type 2 Diabetes Mellitus If Metformin is not Considered Appropriate. 27200582 2016 06 10 2016 05 21 1524-4733 17 7 2014 Nov Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research Value Health A Systematic Review and Network Meta-Analysis Assessing the Effectiveness and Tolerability of Gliptins

Full Text available with Trip Pro

2016 Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

9. Gliptin

Gliptin Gliptin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Gliptin Gliptin Aka: Gliptin , DPP-4 Inhibitor , Dipeptidyl Peptidase (...) -4 Inhibitor , Dipeptidyl-Peptidase IV Inhibitor , DPP-4 , Sitagliptin , Januvia , Saxagliptin , Onglyza , Linagliptin , Tradjenta , Alogliptin , Nesina From Related Chapters II. Indications deficiency and Adjunct to , s, s III. Precautions Gliptins are less than half as effective as lower cost medications (e.g. , s) No longterm evidence of improved outcomes Expensive (>$400/month) May consider for those close to goal AND Already either on other s or in whom they are contraindicated (e.g. ) IV

2018 FP Notebook

10. Gliptins-mediated neuroprotection against stroke requires chronic pre-treatment and is glucagon-like peptide-1 receptor independent. (PubMed)

Gliptins-mediated neuroprotection against stroke requires chronic pre-treatment and is glucagon-like peptide-1 receptor independent. Gliptins are anti-type 2 diabetes (T2D) drugs that regulate glycaemia by preventing endogenous glucagon-like peptide-1 (GLP-1) degradation. Chronically administered gliptins before experimental stroke can also induce neuroprotection, and this effect is potentially relevant for reducing brain damage in patients with T2D and high risk of stroke. It is not known (...) , however, whether acute gliptin treatment after stroke (mimicking a post-hospitalization treatment) is neuroprotective or whether gliptin-mediated neuroprotection occurs via GLP-1-receptor (GLP-1R) activation. To answer these two questions, wild-type and glp-1r(-/-) mice were subjected to transient middle cerebral artery occlusion (MCAO). Linagliptin was administered acutely (50 mg/kg intravenously), at MCAO time or chronically (10 mg/kg orally) for 4 weeks before and 3 weeks after MCAO

2016 obesity & metabolism

11. Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes. (PubMed)

Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes. Data on the possible relationship of gliptin treatment with the incidence of acute pancreatitis have been controversial. The aim of the current study was to combine data on the incidence of acute pancreatitis from three large randomized controlled trials.Three trials designed to test cardiovascular safety and efficacy of add-on treatment (...) with a gliptin were included in the analysis, as follows: SAVOR-TIMI 53 (saxagliptin), EXAMINE (alogliptin), and TECOS (sitagliptin). The trials included 18,238 gliptin-treated patients and 18,157 placebo-treated patients. Data were combined using a random-effects model meta-analysis.The incidence of acute pancreatitis was significantly increased in the gliptin-treated patients when compared with the control groups (odds ratio 1.79 [95% CI 1.13-2.82], P = 0.013). The difference in the absolute risk was small

Full Text available with Trip Pro

2016 Diabetes Care

12. Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS (PubMed)

Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS The issue related to macrovascular outcomes and intensive glycemic control was hotly debated after the publication of landmark trials like ACCORD, ADVANCE, and VADT. The only benefits seem to come from intervening early on in the disease process as indicated by the 10-year UKPDS follow-up. To complicate matters USFDA made it mandatory for modern drugs to conduct cardiovascular safety trials in high-risk (...) populations after the 2008 rosiglitazone scare. This led to all the modern group of drugs designing cardiovascular safety trials (gliptins, GLP-1 agonists, and SGLT-2 inhibitors) to meet USFDA regulatory requirements. We saw publication of the first 2 randomized trials with gliptins published a year and a half back. On the face value SAVOR TIMI and EXAMINE satisfied the primary composite CV end-points. However, issues related to significant increase in heart failure and all-cause 7-day on-treatment

Full Text available with Trip Pro

2015 Journal of diabetes research

13. Gliptins - do they increase cardiovascular risk or benefit? (PubMed)

Gliptins - do they increase cardiovascular risk or benefit? In 2008, the US FDA required all new glucose-lowering therapies to show cardiovascular safety, and this applies to the dipeptidyl peptidase-4 inhibitors ('gliptins').The cardiovascular safety trials of saxagliptin and alogliptin have recently been published and are the subject of this evaluation.The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus - Thrombolysis in Myocardial Infarction 53 trial (...) . The effect of alogliptin on hospitalisations for heart failure has not been reported. Neither agent improved cardiovascular outcomes. As there is no published evidence of improved outcomes with gliptins, it is unclear to us why these agents are so widely available for use. We suggest that the use of gliptins be restricted to Phase IV clinical trials until such time as cardiovascular safety and benefits/superiority are clearly established.

2014 Expert opinion on drug safety

14. Is there any evidence around the use of gliptins in patients with stage 4 (GFR 15-29 ml/min/1.73 m2) chronic kidney disease?

Is there any evidence around the use of gliptins in patients with stage 4 (GFR 15-29 ml/min/1.73 m2) chronic kidney disease? Is there any evidence around the use of gliptins in patients with stage 4 (GFR 15-29 ml/min/1.73 m2) chronic kidney disease? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words (...) as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence around the use of gliptins in patients with stage 4 (GFR 15-29 ml/min/1.73 m2) chronic kidney disease? 2010 CKS guidance

2011 TRIP Answers

15. Do any of the newer diabetic drugs [gliptins etc] have a role in weight reduction in PCOS? Is there any experience of use and are they licensed?

Do any of the newer diabetic drugs [gliptins etc] have a role in weight reduction in PCOS? Is there any experience of use and are they licensed? Do any of the newer diabetic drugs [gliptins etc] have a role in weight reduction in PCOS? Is there any experience of use and are they licensed? - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase (...) aim to deliver for every single search. As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Do any of the newer diabetic drugs [gliptins etc] have a role in weight reduction in PCOS

2011 TRIP Answers

16. Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction. (PubMed)

Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction. Medical stimulation of endogenous progenitor cell circulation may serve as a new therapeutic tool for treatment of acute myocardial infarction. We analyzed the effects of antidiabetic gliptins plus GCSF (granulocyte colony stimulating factor) on myocardial regeneration after myocardial infarction in a mouse model.After surgical LAD-ligation (left anterior descending (...) artery), Sitagliptin/Vildagliptin was applied yielding sufficient blood levels verified by mass spectrometry and significantly reducing activity of dipeptidyl peptidase (DPP) IV. GCSF or saline was administered intraperitoneally for 6 days. We assessed stem cell mobilization and homing (flow cytometry), infarct size (histology), neovascularization and cellular proliferation (immunohistology), heart function (Millar tip catheterization) and survival (Kaplan-Meier-curves). Gliptins±GCSF administration

2013 International journal of cardiology

17. Prescribing gliptins: Enthusiasm should be coupled with caution (PubMed)

Prescribing gliptins: Enthusiasm should be coupled with caution 22470884 2012 10 02 2018 11 13 2230-9500 16 2 2012 Mar Indian journal of endocrinology and metabolism Indian J Endocrinol Metab Prescribing gliptins: Enthusiasm should be coupled with caution. 324-5 10.4103/2230-8210.93785 Garg M K MK Department of Endocrinology, Army Hospital (Research and Referral), Delhi Cantonment, India. Kharb Sandeep S Pandit Aditi A eng Journal Article India Indian J Endocrinol Metab 101555690 2230-9500 2012

Full Text available with Trip Pro

2012 Indian journal of endocrinology and metabolism

18. Gliptin

Gliptin Gliptin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Gliptin Gliptin Aka: Gliptin , DPP-4 Inhibitor , Dipeptidyl Peptidase (...) -4 Inhibitor , Dipeptidyl-Peptidase IV Inhibitor , DPP-4 , Sitagliptin , Januvia , Saxagliptin , Onglyza , Linagliptin , Tradjenta , Alogliptin , Nesina From Related Chapters II. Indications deficiency and Adjunct to , s, s III. Precautions Gliptins are less than half as effective as lower cost medications (e.g. , s) No longterm evidence of improved outcomes Expensive (>$400/month) May consider for those close to goal AND Already either on other s or in whom they are contraindicated (e.g. ) IV

2015 FP Notebook

19. Gliptins: A New Class of Oral Antidiabetic Agents (PubMed)

Gliptins: A New Class of Oral Antidiabetic Agents India has the largest population of patients with type 2 diabetes mellitus. The conventional agents used to treat type 2 diabetes frequently exhibit reduced efficacy over time leading to inadequate glycaemic control and are also associated with adverse effects. Hence, there is a need for alternative therapies that can overcome the limitations associated with conventional antidiabetic agents. This review focuses on Gliptins, which have become (...) a research area of intense focus and present an alternative therapeutic strategy for patients with type 2 diabetes. Gliptins show significant improvements in glycaemic control and are well tolerated, particularly with regard to weight change and hypoglycemia. Hence, gliptins are considered as useful agents for the treatment of type 2 diabetes mellitus.

Full Text available with Trip Pro

2009 Indian journal of pharmaceutical sciences

20. Nine different drug classes reviewed for type 2 diabetes

types of blood glucose lowering drugs in this study were: Basal insulin (long-acting insulin detemir or insulin glargine) Metformin (a biguanide) Sulphonylureas (e.g. glibenclamide, glipizide) Thiazolidinedione (pioglitazone is the only authorised drug) DPP-4 inhibitor (gliptins, e.g. sitagliptin) SGLT-2 inhibitor (e.g. dapaglifozin) GLP-1 receptor agonist (incretin mimetics, e.g. exenatide) α-glucosidase inhibitor (acarbose) Meglitinides (prandial glucose regulators, or glinides, e.g. repaglinide

2019 NIHR Dissemination Centre

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>